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Hui Zhou1,2†, Kun Tang1,2†, Haibing Xiao1,2, Jin Zeng1,2, Wei Guan1,2, Xiaolin Guo1,2, Hua Xu1,2* and Zhangqun Ye1,2Abstract
Background: There is increasing evidence to suggest that miRNAs play an important role in predicting cancer
survival. To identify a panel of miRNA signature that can divided tumor from normal bladder using miRNA
expression levels, and to assess the prognostic value of this specific miRNA markers in bladder cancer (BCa).
Methods: A comprehensive meta-review of published miRNA expression profiles that compared BCa and adjacent
normal tissues was performed to determine candidate miRNAs as prognostic biomarkers for BCa. Vote-counting
strategy and Robust Rank Aggregation method were used to identify significant meta-signature miRNAs.
Results: We identified an eight-miRNA signature including three upregulated (miR-141, miR-200c, miR-21) and five
downregulated (miR-145, miR-125, miR-199a, let-7c and miR-99a) miRNAs for the prediction of overall survival (OS)
using TCGA dataset, and validated in our 48 BCa patients. X-tile plot was used to generate the optimum cut-off
point and Kaplan-Meier method was used to calculate OS. A linear prognostic model of eight miRNAs was constructed
and weighted by the importance scores from the supervised principal component method to divide patients into
high- and low-risk groups. Patients assigned to the high-risk group were associated with poor OS compared with
patients in the low-risk group (HR = 5.21, p < 0.001). Our validation cohort of 48 patients confirmed the panel of
8-miRNAs as a reliable prognostic tool for OS in patients with BCa (HR = 5.04, p < 0.001).
Conclusion: The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs
from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value
that complements traditional clinicopathological risk factors.
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Bladder cancer (BCa) is the top ten malignancy of all
adult cancer and its incidence has increased over recent
decades [1]. Current prognostic factors, namely tumor
node metastasis (TNM) stage and pathological grade,
are insufficient to predict individual clinical outcome [2].
These clinicopathological risk factors do not clearly dis-
tinguish between patients who have a high or low risk of
disease recurrence, chemotherapy response and overall
survival (OS). Thus there is a need to add new prognostic* Correspondence: xuhuawhu@163.com
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which also could be used as therapeutic targets.
MicroRNAs (miRNAs), a class of short, single-stranded
and highly conserved noncoding RNA molecules, is
recently discovered and shown to regulate gene expres-
sion at the post-transcriptional level, by binding
through partial sequence homology, to the 3′-untrans-
lated region (3′-UTR) of target mRNAs and causing
translational inhibition or mRNA degradation. Recent
evidence indicates a regulatory role for miRNAs in cancer
development and progression, suggesting that miRNAs
function as oncogenes or cancer suppressor genes in a
tissue-specific manner [3]. MiRNAs also function in
tumor cell proliferation, apoptosis, invasion and tumor
vessel formation via the regulation of downstream targetedicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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pression is related to overall survival, disease stage and the
development of metastases and recurrences. Interestingly,
recent studies proposed miRNA signature as promising
biomarkers for early cancer detection and accurate prog-
nosis as well as targets for more efficient treatment [4]. To
date, only a few reports have described miRNA expression
and its association with survival in bladder cancer.
MiRNA profiling datasets were emerging rapidly with
the employ of high-throughput technologies. However,
recent microarray datasets for miRNA showed inconsist-
ent results between the studies due to different techno-
logical platforms and small sample size application.
Considering the inconsistent annotation and ongoing
discovery of new miRNAs, different detection methods
used by different technological platforms and various
methods for data processing and analysis, we are trying
to find a meaningful way to increase the statistical power
of microarray data by integrating the results of several
individual studies. Hence, we performed an integrated
miRNA expression profiling analysis to identify gene
coexpression networks and to define more robust sets of
cancer-related genes and miRNAs in BCa. The existing
limitations on miRNA research prompted us to perform
an integrated miRNA expression profiling analysis so as
to (i) compare and validated the expression profiles of
miRNA in BCa in comparison with NT, (ii) explore
meta-signature miRNAs that consistently dysregulated
expressed in BCa and their bioinformatics function, (iii)
identify possible associations between miRNA expres-
sion patterns and OS in BCa, (iv) construct a prognostic
model combing meta-signature miRNAs based panel
and (v) provide a reliable prognostic and predictive
biomarker that complements the traditional clinico-
pathological prognostic factors.
Material and methods
Selection of studies and datasets
Study selection
A systematic review of the literature was performed to
identify miRNA expression profiling datasets compar-
ing bladder cancer vs. normal tissue published up to
Nov 2014. We conducted a systematic search of the
electronic databases, including PubMed, GEO profile,
TCGA and Oncomine dataset, using the MESH search
headings: (mirna OR microrna OR mir-) AND profile
AND (bladder urothelial) AND (cancer OR tumor OR
carcinoma).
Inclusion criteria and exclusion criteria
To be included in the analysis, studies should meet the
following criteria: (i), they were bladder cancer miRNA
expression profiling studies; (ii), they used tissue samples
obtained from surgically resected bladder cancer andcorresponding adjacent or normal tissues for compari-
son; (iii), they reported the relative miRNAs expression
using miRNA microarray, sequencing methods or directly
qRT-PCR.
Studies were excluded in the meta-analysis if: (i) the in-
clusion criteria were not met, (ii) no outcomes of interest
were reported or the necessary data were impossible to
calculate or extrapolate from the published results, (iii)
studies used the serum, plasma, exosome or urine samples
of bladder cancer patients or cell lines, and (iv) the studies
compared miRNA expression profiles in invasive and non-
invasive bladder cancer.
Data extraction
Two reviewers (TK & ZH) extracted independently the
following data including: first author, year of publication,
country, study interval, assay type, No. of probes, cancer
type, stage, No. of samples and the list of up- and down-
regulated miRNA features, and their relative fold change.
All disagreements about eligibility were resolved by dis-




Vote-counting rank based of ranking potential molecular
biomarkers was widely adopted in the meta-analysis [5].
The miRNAs were ranked according to their importance
as follows: (i) number of comparisons consistently re-
ported; (ii) total number of samples for comparison in
agreement; (iii) average fold-changes reported for com-
parisons in agreement. Total sample size was considered
more important than average fold-change because many
studies did not report a fold-change.
Robust rank aggregation analysis
The list of extracted miRNAs was ranked based on
their associated p-values (less than 0.05 was considered
significant) when their fold-changes were not reported.
All of the protocols for the Robust Rank Aggregation
method are free to download at the comprehensive R
Archive Network website (http://cran.r-project.org/).
Details can be found in the package documentation
(http://cran.r-project.org/web/packages/RobustRankAg-
greg/RobustRankAggreg.pdf ). This method assigns a
p-value to each element in the aggregated list, which
indicates how much better it is ranked compared with
a null model, expecting random ordering [6].
Cluster analysis of datasets
To assess the correlations between the results of individual
datasets, hierarchical cluster analysis was used. Overall
rank matrix was constructed based on rank matrixes
obtained from separate analyses for upregulated and
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means that this miRNA was not reported in that study,
value above 0.5 means it is upregulated (one minus
normalized rank of miRNA from the analysis of upreg-
ulated gene lists) and value below 0.5 means that this
miRNA is downregulated in that study (normalized
rank from analysis of downregulated gene lists). In clus-
ter analysis, Spearman rank correlation with average linkage
method was used.
miRNA target prediction
The putative targets of meta-signature miRNAs were
predicted using databases utilizing three different tar-
get prediction algorithms. The mRNA targets of the
miRNA genes were predicted using TargetScan (http://
www.targetscan.org/), PicTar (http://pictar.mdc-berlin.
de/), miRWalk (http://www.umm.uni-heidelberg.de/apps/
zmf/mirwalk/), miRDB (http://mirdb.org/miRDB/), and
miRANDA (http://www.microrna.org/microrna/get Gene-
Form.do), as each algorithm determines target binding dif-
ferently. We selected targets with scores less than −1.25 for
further analysis.
Enrichment analysis
A list of the potential targeted genes of each miRNA
was submitted to DAVID Bioinformatics Resources 6.7
(http://david.abcc.ncifcrf.gov) to acquire the gene an-
notation, and a graph of signaling pathways for BCa
carcinogenesis in which the target genes may be involved
was generated using the KEGG pathways program (http://
www.genome.jp/kegg/pathway.html). All statistical ana-
lyses were performed using Stata 10.0 software (StataCorp
LP, College Station, TX) with two-tailed tests; statistical
significance was defined as p < 0.05.
Creation of a prognostic index model using the panel of
8-miRNAs signature based on TCGA dataset
Bladder cancer TCGA miRNA dataset
MiRNA expression data and corresponding clinical data
for 84 bladder cancer patients were obtained from The
Cancer Genome Atlas (TCGA) data portal [TCGA Data
Portal.[https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp]].
Both the miRNA expression data and clinical data, includ-
ing outcome and staging information of TCGA patients
deposited at the Data Coordinating Center (DCC), are
publically available and open-access. TCGA data are clas-
sified by data type (clinical, mutations, gene expression)
and data level, to allow structured access to this resource
with appropriate patient privacy protection. This study
meets the publication guidelines provided by TCGA
[Publication Guidelines. [http://cancergenome.nih.gov/
publications/publicationguidelines]]. Normalized miRNA
expression data were collected from the TCGA Data
Portal using the Arraytool [7].Prognostic value of each meta-signature miRNA in the
TCGA dataset
SurvMicro (http://bioinformatica.mty.itesm.mx:8080/Bio
matec/Survmicro.jsp) was used to investigate the relation-
ship between each miRNA and overall survival within
different independent classes of disease stage. The Kaplan-
Meier and log-rank test were performed to test the
equality for survival distributions in different groups.
Hazard ratios (HRs), the ratio of hazards for a 2.5-fold
change in the miRNA relative prognostic index, from
survival analysis were used to identify candidate miRNAs
associated with OS.
Prognostic index model creation using the 8-miRNAs
signature based on multivariate Cox survival analysis
The TCGA validated method was used to develop a prog-
nostic model of the weighted linear combination of the
meta-signature miRNAs expression levels. This algorithm
is based on an importance score assigned to each miRNA,
calculated by the supervised principal components method.
Using the Cox regression models, we calculated a risk
score for each patient based on their individual expression
levels of the eight miRNAs, where prognostic index (risk
score) = (0.465 × expression value of miR-200c) - (0.607 ×
expression value of miR-141) - (0.294 × expression value of
miR-21) + (0.085 × expression value of miR-99a) + (0.578 ×
expression value of miR-125b) - (0.218 × expression value
of miR-199a) - (0.064 × expression value of miR-145) -
(0.146 × expression value of let-7c).
Validation of the 8-miRNAs signature expression using
qRT-PCR
Sample collection
Forty-eight BCa and adjacent normal tissue samples
(collected post-operatively from Dec 2010 to Dec 2014)
used in this study were obtained from the Department
of Urology in Tongji Hospital of Huazhong University
of Science and Technology (Wuhan, China). The speci-
mens were obtained from patients undergoing BCa re-
section with curative intent. All the diagnoses were
based on pathological assessments. Upon removal of
the surgical specimen, each sample was immediately
frozen in liquid nitrogen and stored at −80 °C prior to
RNA isolation and qRT-PCR analysis.
RNA extraction and qRT-PCR
Total RNA was isolated from the frozen tissue sample
with TRIzol (Invitrogen) according to the manufacturer’s
instructions. First-strand complementary DNA (cDNA)
was synthesized from 2 μg of the total RNA using an
oligo-dT primer and superscript II reverse transcriptase
(Invitrogen). Then, quantification of the most up-
regulated or down-regulated miRNAs was performed by
qRT-PCR using SYBR Premix Ex Taq on MX3000
Fig. 1 Heat map shows relative fold change of miRNAs in bladder
cancer compared with normal adjacent tissue as reported by eligible
studies. Hierarchical clustering of 19 selected studies and datasets
with the 49 deferentially expressed miRNAs using average linkage
clustering. Here we selected 52 miRNAs (26 down-regulated miRNAs
and 26 up-regulated miRNAs) which reported in at least five expression
profiling studies. Every row represents an individual miRNA, and each
column represents an individual dataset. Acronyms are explained in
Additional file 3: Table S1 and the number of miRNAs analyzed in each
study is graphically depicted on the right. Pseudocolours indicate
transcript levels from low to high on a log 2 scale from −3 to 3,
ranging from a low association strength (dark, black) to high
(bright, red, or green). Short red and green vertical bars indicate
upregulated and downregulated miRNAs, respectively. While the
black bar with the pseudocolours 0 means that there is no available
data reported in the primary studies
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poeia. PCR was performed in a real-time PCR system as
follows: 95 °C for 10 min, followed by 40 cycles of 95 °C
for 10 s, 60 °C for 20 s and 72 °C for 30 s, and then 95 °C
for 1 min and 60 °C for 1 min. All experiments were done
in triplicate. The expression level values were normalized
to those of the small nuclear RNA U6 as a control. Rela-
tive fold-changes of miRNA expression were calculated
using the △△CT method, and the values were expressed as
2-△△CT.
Validation of the 8-miRNAs signature for predicting
survival in bladder cancer
Follow-up
The length of follow-up was calculated from the date of
surgery to the date of last clinical follow-up. The spectrum
of clinical follow-up included a history, physical examin-
ation, and routine biochemical examination.
Survival analysis
For survival analysis, we used the Kaplan-Meier method
to analysis the correlation between recurrence-free sur-
vival, overall survival and the panel of 8-miRNAs signa-
ture, and the log-rank test was used to compare survival
curves. We selected the optimum cut-off value for the
8-miRNAs signature using X-tile plots based on the
association with the patients’ RFS and OS. X-tile plots
provide a single and intuitive method to assess the asso-
ciation between variables and survival. The X-tile pro-
gram can automatically select the optimum data cut
point according to the highest χ2 value (minimum
p value) defined by Kaplan-Meier survival analysis and
log-rank test [8]. We did the X-tile plots using the X-tile
software version 3.6.1 (Yale University School of Medicine,
New Haven, CT, USA).
Results
Selection and a short overview of the datasets
A total of 19 bladder cancer (BCa) miRNA expression
profiles were identified for this meta-analysis (Additional
file 1: Figure S2). An expanded description of the design
strategy is available in Additional file 2: Figure S1. First
author, year of publication, acronym, country, period,
cancer type, stage, sample size, microarray platform, No.
of probes and cut-off criteria were extracted individually
from each study and listed in Additional file 3: Table S1.
A short description of the studies and the acronyms by
which the studies are referred to in the following text is
also provided in Additional file 3: Table S1.
798 different expressed miRNAs were reported in the
19 miRNA expression profiling datasets; 54 were up-
regulated (Additional file 4: Table S2) and 49 were
down-regulated (Additional file 5: Table S3) in at least
three datasets. Although there were differences betweenthe individual miRNA profiling datasets, the top lists of
the deregulated miRNAs remained consistent from study
to study.
To display the concordance of differentially miRNA
profiling datasets more direct-viewing, heat-map and
hierarchical clustering analysis were performed (Fig. 1).
It shows that the results of the studies tend to cluster
mainly according to utilized profiling platform. It also
clearly shows that most of the miRNA are consistently







hsa-miR-141-3p 5.51E-11 6.47E-13 8
hsa-miR-200c-3p 4.62E-10 5.33E-12 8
hsa-miR-21-5p 2.58E-9 4.42E-11 6
Down-regulated
hsa-miR-145-5p 3.46E-11 4.25E-13 16
hsa-miR-125b-5p 6.71E-11 7.94E-13 12
hsa-miR-199a-5p 5.44E-10 6.38E-12 10
hsa-let-7c 2.31E-09 4.18E-11 9
hsa-miR-99a-5p 8.78E-08 9.32E-10 8
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signature miRNAs are the frenquently reported, whereas
only one study CH reported a reversed result of miR-
141 expression in BCa [9].
Identification of the eight-miRNAs signature
We identified a statistically significant meta-signature of
three upregulated and five downregulated miRNAs using
robust rank aggregation (Table 1). Eight of the most sig-
nificantly dysregulated miRNAs, miR-141, miR-200c,
miR-21, miR-145, miR-125b, miR-199a, let-7c and miR-
99a are reported in the majority of the datasets (8, 8, 6,
16, 12, 10, 9 and 8, respectively, Table 2). The direction
of expression change of meta-signature miRNAs is con-
sistent across all studies. The two meta-signature upreg-
ulated miRNAs (miR-141, miR-200c) belong to the
cluster of miR-200 family which plays an important in
tumor epithelial-mesenchymal transition (EMT). Our re-
sults from the vote-counting strategy were almost the
same with those from the Robust Rank Aggregation
method.
A total of 8676 genes were identified as potentially tar-
gets of miRNAs contained in the eight-miRNA signa-
ture. We used six up-to-date prediction algorithms
(TargetScan, PicTar, miRanda, miRWalk, miRDB and
DIANA) to identify conservative target genes that could
be predicted by the selected eight meta-signature miR-
NAs. We observed an overlap of targeted genes enriched
in the eight meta-signature miRNAs. Geneset enrich-
ment analysis found that meta-signature miRNAs co-
operatively target functionally related and biologically
relevant genes in signaling and developmental pathways.
The top ten GO processes and pathways that were most
strongly enriched with respect to the meta-signature
miRNA candidates are shown in Table 2. This analysis
revealed an overrepresentation of the predicted miRNA
targets involved in the critical pathway linked to carcino-
genesis such as: intracellular signaling cascade, ErbBsignaling pathway, pathways in cancer, p53 signaling
pathway, MAPK signaling pathway, and renal cell car-
cinoma. These indicate a potentially important func-
tional role of selected meta-signature miRNAs in the
progression of bladder cancer. Taken together, these ex-
ploratory analyses suggested that deregulation of the
eight miRNAs might affect the critical pathways involved
in cancer progression. We also had a review of the identi-
fied eight meta-signature miRNAs and their involvement
in cancer pathogenesis in bladder cancer (Additional file 6:
Table S4).
Creation of the eight-miRNAs signature and its association
with BCa overall survival in TCGA dataset
We identified eight dysregulated meta-signature miRNAs
in BCa, and bioinformatics analysis revealed important
biological function in BCa progression. Then we tried to
evaluate the prognostic power of the eight-signature miR-
NAs using the TCGA dataset of bladder cancer. Fig. 2
shows the distribution of patient prognostic scores, the
survival status and tumor miRNA expression of all 84
TCGA BCa patients, ranked according to the prognostic
score values for the eight-miRNA signature. Of all these
eight miRNAs, six were associated with high risk (miR-21,
miR-145, miR-125b, miR-199a, miR-99a, and let-7c) and
two were shown to be protective (miR-200c and miR-141)
(Fig. 3a). BCa with high prognostic scores tended to ex-
press high-risk miRNAs, whereas BCa with low prog-
nostic scores tended to express protective miRNAs
(Fig. 3d and e). Patients with high-risk prognostic scores
had more chance of death than low-risk-score patients.
The max risk cutoff point was used for the TCGA pa-
tient cohort to classify the patients into either high-risk
or low-risk groups. We then derived a formula to calcu-
late the prognostic index (risk score), weighted by re-
gression coincident based on multivariate Cox analysis
of the 8-singature miRNAs. Patients expressing the
high-risk miRNA signature exhibited poorer OS than
patients expressing the low-risk miRNA signature (HR =
5.21, p < 0.001). Kaplan-Meier curves for the high-risk
and low-risk groups within the TCGA cohort (n = 84)
are shown in Fig. 3b. Time-dependent ROC curves were
used to assess the prognostic power of the eight-miRNA
signature. The area under curve (AUC) for the eight-
miRNA signature prognostic model was 0.74 (p < 0.01,
Additional file 7: Figure S12). We also elevated the pre-
dictive value of single miRNA, all of which were signifi-
cantly associated with overall BCa survival in the
TCGA dataset (p < 0.01, Additional file 8: Figure S3,
Additional file 9: Figure S4, Additional file 10: Figure S5,
Additional file 11: Figure S6, Additional file 12: Figure S7,
Additional file 13: Figure S8, Additional file 14: Figure S9,
Additional file 15: Figure S10). A list of survival analysis
using TCGA datasets upon relative miRNAs that refered
Table 2 Ten GO processes and pathways most strongly enriched by meta-signature miRNA targets
GO processes Process p-Value Benjamini Genes
0035556: intracellular signaling cascade 7.8E-13 3.3E-9 258
0007167: enzyme linked receptor protein signaling pathway 9.3E-10 2.0E-6 89
0006796: phosphate metabolic process 1.1E-8 1.1E-5 194
0007169: transmembrane receptor protein tyrosine kinase signaling pathway 9.6E-8 8.2E-5 61
0035556: protein kinase cascade 1.1E-7 7.8E-5 88
0006468: protein amino acid phosphorylation 2.2E-7 1.2E-4 138
0006355: regulation of transcription 2.4E-7 1.1E-4 435
0019220: regulation of phosphate metabolic process 2.5E-7 9.5E-5 107
0031328: positive regulation of cellular biosynthetic process 1.7E-6 3.7E-4 137
0043549: positive regulation of cell proliferation 2.6E-6 4.7E-4 91
KEGG Pathways Pathway p -Value Benjamini Genes
04722: Neurotrophin signaling pathway 5.0E-12 9.1E-10 49
04012: ErbB signaling pathway 8.2E-8 7.5E-6 33
05220: Chronic myeloid leukemia 9.5E-8 5.7E-6 30
05200: Pathways in cancer 1.7E-7 7.6E-6 81
04520: Adherens junction 1.9E-7 6.8E-6 30
04910: Insulin signaling pathway 1.6E-6 4.3E-5 41
05215: Prostate cancer 1.8E-6 4.1E-5 31
04722: p53 signaling pathway 8.0E-6 1.6E-4 25
04010: MAPK signaling pathway 1.2E-5 2.2E-4 64
05211: Renal cell carcinoma 1.4E-5 2.3E-4 25
Panther pathways Pathway p -Value Benjamini Genes
P00018: EGF receptor signaling pathway 6.3E-6 7.9E-4 43
P00047: PDGF signaling pathway 1.9E-4 8.1E-3 47
P04398: p53 pathway feedback loops 2 2.0E-4 6.4E-3 22
P00059: p53 pathway 3.5E-4 8.8E-3 34
P00021: FGF signaling pathway 6.8E-4 1.4E-2 36
P04393: Ras Pathway 3.5E-3 6.1E-2 25
P04397: p53 pathway by glucose deprivation 6.4E-3 9.6E-2 11
P00042: Muscarinic acetylcholine receptor 1 and 3 signaling pathway 8.3E-3 1.1E-1 18
P00039: Metabotropic glutamate receptor group III pathway 1.2E-2 1.4E-1 21
P00034: Integrin signalling pathway 1.6E-2 1.2E-1 47
The number of predicted target genes in the process or pathway is shown
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:53 Page 6 of 12in at least three datasets were showed in Additional file
16: Figure S11 and Additional file 17: Table S5.
Experimental validation of the relative expression levels
of the eight-miRNAs in patients with bladder cancer
Considering of the basis of the miRNA microarray results,
we further examined BCa-associated miRNAs expression
using qRT-PCR to analysis the 48 BCa samples in different
sets so as to assess and validate the prognostic value of
candidate miRNAs. Our cohort of bladder cancer patients’
clinicopathological characters was listed in Additional
file 18: Table S6. We selected the panel of eight meta-
signature miRNAs for the validated qRT-PCR analysis.The results showed that the expression levels of miR-
21, miR-141 and miR-200c were increased, whereas the
levels of miR-145, miR-125b, miR-199a, miR-99a and
let-7c were decreased in the BCa tissues compared with
adjacent normal tissue (all p < 0.01). Detailed data are
available in Additional file 19: Figure S13.
To display the relative expression of differentially
miRNA more direct-viewing, heat-map and hierarchical
clustering analysis were also performed (Fig. 4). Short
red and green vertical bars indicate upregulated and
downregulated miRNAs, respectively. Using hierarchical
clustering, based on the differentially expressed miR-
NAs, we could successfully separate the 8 miRNAs into
Fig. 2 miRNA predictor-score analysis of 84 patients in TCGA cohort. Information related to censoring event being analyzed (risk group assignment
(a), censoring status (b), time related to event (c), and prognostic index (d). Color-gram of miRNA expression profiles of TCGA patients. miRNA expression
profiles shown as a heatmap helping in the analysis and visual correlation of the survival analysis and gene expression. Samples are shown in x-axis while
genes are shown in y-axis (e). The genes are clustered by Euclidean distance. The patients’ ID showed under the figure (f)
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downregulated miRNAs (Fig. 4a).
Validation of the 8-miRNAs signature for predicting survival
in bladder cancer
The same prognostic score formula obtained from the
TCGA dataset was used to calculate the eight-miRNA
signature score for each of our 48 patients in the valid-
ation cohort. We used X-tile plots to generate the
optimum cut-off point for the eight-signature miRNAs
in our validation cohort (Fig. 4b, c, d). Cox regression
analysis validated the panel of eight-miRNA signature as
a potential prognostic biomarker (HR: 5.04, 95%CI: 1.85-
13.75, p = 0.0016).
Discussion
Recent studies indicated miRNAs played an important
role in predicting OS in BCa. Here, we performed an inte-
grated analysis approach to analyze BCa specific miRNAs
derived from independent profiling datasets. We used
robust rank aggregation method and identified a meta-
signature of three upregulated and five downregulated
miRNAs. Deriving from TCGA dataset, we identified
eight-miRNA signature and constructed a prognosticmodel closely associated with both biological function
and clinical survival. Our validation also highlighted
the potential of miRNA panel to facilitate clinical prog-
nosis prediction in patients with BCa.
We compared and validated the expression miRNA in BCa
with NT
Our cluster-analysis distinguished the significantly up-
regulated and downregulated miRNAs in BCa compar-
ing to NT, however, recent miRNA expression profiling
datasets are lack of inconsistent results between the
studies due to different technological platforms and lab
protocols as well as small sample sizes application. This
inconsistence may be also caused, at least in part, by
fundamental, methodological differences in the preselec-
tion of candidate miRNAs. Although the preferred
method for miRNA expression meta-analysis involves
analysis of the raw expression datasets that are pooled
together, such rigorous approach is often not possible
due to the unavailability of the raw data. Variations in
the number of miRNAs known at the moment and the
technological platform employed in any particular study
make the proper integration of raw datasets very compli-
cated. In addition, the relatively small sample size and
Fig. 3 The eight-miRNA signature was tightly associated with prognosis in TCGA dataset. Box plot visualizing the expression levels of each miRNA
in the risk groups generated (a). The cutoff value divided patients into low-risk and high-risk groups according to miRNA signature expression,
and risk group splitting was optimized using a simple algorithm shown in the section Risk Groups Plots using the inner-group p-value. Kaplan-Meier
overall survival analysis showed the eight-miRNA signature could predict the clinical outcome of TCGA (b)
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ency of biological conclusions.
For example, Liu et al. reported that miR-200c was
down-regulated in bladder cancer tissues and cell lines
[10]. According to our integrated analysis based 19
miRNA profiling datasets and validation, miR-200 family
were up-regulated in BCa compared with normal tissue.
However, as we all knew miR-200c was tightly associated
with EMT, and up-regulated miR-200c could inhibit pro-
liferation, invasion and migration in cancer progression.
It seemed contradictory between miR-200c relative ex-
pression and its biological function. However, we found
miR-200c was downregulated in invasive comparing
non-invasive BCa. Therefore, we could still say up-
regulated miR-200 family inhibit EMT and provide fa-
vorable prognosis in BCa. So, the authors might reverse
miRNA expression just to meet expectation of its tumor
function. Here, we confirmed that miR-200c wasupregulated in BCa vs. NT, and downregulated in inva-
sive vs. noninvasive BCa, also miR-200c was downregu-
lated in BCa urine vs. normal urine [11], while circulating
miR-200b was upregulated in plasma [12] and serum [13].
Also, miR-199a-3p is highly expressed in hair follicles and
in some tumor cells, suggesting its participation in tumor
progression, but it is significantly downregulated in hepa-
tocellular carcinoma and in bladder cancer.
We identified an eight-miRNA signature closely associated
with both biological function and clinical survival
In this study, we selected common miRNAs related to
clinical outcome as the potential prognostic miRNAs.
Among the eight miRNAs, miR-21 has been validated as
a prognostic and predicative biomarker in various can-
cers [14]. miR-21 is shown to significantly upregulated
in tumor tissues and may modulates cell proliferation
and sensitivity to doxorubin [15]. MiR-21 is found to
Fig. 4 Expression and Kaplan-Meier overall survival analysis of the eight-miRNAs signature in our validation cohort of 48 bladder cancer patients.
Heat map shows relative fold change of miRNAs in bladder cancer compared with normal adjacent tissue determined by qRT-PCR (a). Hierarchical
clustering of 48 paired tumor tissues and adjacent normal tissue with the 8 deferentially expressed miRNAs using average linkage clustering. Every
row represents an individual miRNA, and each column represents an individual sample. Pseudocolours indicate transcript levels from low to high
on a log 2 scale from −3 to 3, ranging from a low association strength (dark, black) to high (bright, red, or green). Kaplan-Meier recurrence-free
survival and overall survival analysis by X-tile plots cut-off point (b, c, d). X-tile plots of training sets are shown in the left panels. The plot showed
the chi-squared log-rank values created when the cohort was divided into two groups. The optimal cut-point highlighted by the black circle in
the left panels (b) is shown on a histogram of the entire cohort (middle panels, c) and a Kaplan-Meier plot (right panels, d). P value was determined by
using the cut-point defined in the training subset to parse a separate validation subset. The optimal cut-point for prognostic index determined by
X-tile analysis from the validation cohort and reached high statistical significance
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contrast to low-grade ones [16], also it may serve as in-
dependent prognostic factors for overall survival and
recurrence [17], thus it has the prospect of becoming
candidate biomarker for BCa.
MiR-200 family appears to control the EMT process
and sensitivity to EGFR therapy in bladder cancer cells
[18]. MiR-141 is upregulated in bladder cancer com-
pared to NT. However, increased expression of miR-141
is independently associated with favorable prognosis of
bladder cancer patients, thus it may serve as a promising
biological marker for diagnosis and risk evaluation of
bladder cancer. However, no study had reported the
function of miR-200b in BCa, which need to be further
investigated.
MiR-125b was found to regulate G1/S transition
through the E2F3-Cyclin A2 signaling pathway [19]. Re-
cent findings show that upregulation of miR-125b inhib-
ited proliferation, motility and increased apoptosis by
suppressing SIRT7 and MALAT1 [20]. It can also sup-
presses cell migration and invasion by directly targeting
matrix metalloproteinase 13 (MMP13) in bladder cancer
and may be promising molecular marker and therapeutic
target to inhibit bladder cancer metastasis [21]. Takentogether, these studies indicate that miR-125b may act as a
tumor suppressor in bladder cancer and downregulation
of miR-125b may contribute to the tumorigenesis and
development.
MiR-143/-145 cluster located at chromosome 5q33,
a well-known fragile site in human genome. As ex-
pected, we found that these two miRNAs were highly
co-downregulation in bladder cancer. MiR-143 and
miR-145 have well-documented antiproliferative and
proapoptotic effects due to their ability to downregu-
late a host of target genes, including plasminogen acti-
vator inhibitor-1 (PAI-1) [22], FSCN1 [23], PAK1 [24]
and insulin-like growth factor receptor I (IGF-IR) [25].
These two miRNAs have also been reported to be impli-
cated in Kras regulation and apoptosis avoidance. More-
over, by targeting socs7, exogenous miR-145 can promote
the nuclear translocation of STAT3, which regulates the
IFN-β induction [26]. Several studies have also demon-
strated that miR-143 and miR-145 inhibit multiple tumor
survival effectors, thus exerting antitumor effect in cancer
therapy. For instance, via regulating PI3K/Akt and MAPK
signaling pathways, the growth of bladder cancer cells is
attenuated after replacement treatment with miRNA-143
and −145 [27].
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pressor by inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor
3 (FGFR3) in bladder cancer [28]. Furthermore, the ex-
pression of miR-99a was investigated and shown to be
decreased in plasma of bladder cancer patients, which
strongly supported miR-99a as the potential diagnostic
marker of bladder cancer.
For the remaining two miRNAs (let-7c and miR-199a-
5p), to our knowledge, are less studied in bladder cancer.
MiR-199a-5p is downregulated in bladder cancer and
seems to suppress chemoresistance by targeting the
endoplasmic reticulum chaperone and signaling regula-
tor GRP78 [29]. Let-7c might play a role in the bladder
cancer pathway along with other miRNA and genes [30].
Our gene ontology and pathway enrichment analysis in
silico based on the putative targeted genes, suggested that
variation in miRNAs expression might affect critical path-
ways involved in BCa progression. A better understanding
of the targeted genes of the miRNAs would advance their
use in clinical settings. As shown in Additional file 6: Table
S4, dysregulated miRNAs in RCC involved in cancer patho-
genesis in other malignancies with universal biological
function and targeted genes. Since target prediction algo-
rithms generate certain false negatives and false positives,
further investigations is warranted in our sequent study.
We constructed a reliable prognostic model based miRNA
expression using TCGA dataset and our validation cohort
Because of the lack of cancer specificity and sensitivity,
single miRNA has limitation in the prognostic and pre-
dicative of BCa. Recently, many studies emerging identi-
fied the important role of special miRNA signature in
predicating cancer progression [31, 32]. Liu et al. identi-
fied a five-miRNA signature which might add prognostic
value to the TNM staging system and optimize treat-
ment decisions for patients at high risk of progression in
nasopharyngeal carcinoma [4]. In another study, Chen
et al. analyzed the miRNA expression profile of 119
paired ESCC samples by microarray and identified a
four-miRNA signature that predicted patient survival
[33]. Zhang et al. identified a six-miRNA-based classifier
as a reliable prognostic and predictive tool for disease
recurrence in patients with stage II colon cancer, and it
might be able to predict which patients might benefit
from adjuvant chemotherapy [34]. Since we considered
single miRNA had limit in predicting BCa survival,
therefore, we built a classifier based on the eight miR-
NAs: miR-21, miR-200c, miR-141, miR-145, miR-125b,
miR-199a, let-7c and miR-99a.
Advantage and limitation
Up to date, no integrated analysis of miRNA profiling
studies has investigated in BCa specially. The presentmeta-analysis has been proved to be useful in exploring
candidate miRNA biomarkers in human BCa. The present
study suggested eight promising miRNAs that have been
consistently reported with fold change. Their potential tar-
gets may provide some clues of miRNAs in tumorigenesis
and the underlying mechanisms.
However, we should admit that there exist certain limi-
tations in our integrated network analysis. The major limi-
tation of this study is the inconsistently results of eligible
miRNA expression profiling datasets detected with differ-
ent technological platforms. Second, the sample size of
TCGA dataset we used for the prognostic model creation
was limited to 84 patients. Third, present study was retro-
spective validation with small sample sizes. Therefore, our
conclusion should be further validated by prospective
study in multicentre clinical trials. Fourth, our analysis is
limited to comparison of tumor and normal only. MiR-
NAs that distinguish invasive vs. non-invasive BCa and
different BCa histological subtype were also needed to ex-
plore. Lastly, current miRNA profiles are only limited to
tissue. From the clinical point of view, it would be more
interesting to explore non-invasive biomarkers associated
with patient diagnosis, survival, disease aggressiveness or
response to therapy. For this tissue resection based
miRNA classfier would be just suitable for BCa prediction
after cystectomy. Considering on this, we are now explor-
ing non-invasive circulating miRNAs in plasma and urine
which would be more meaningful for early detection and
precise prediction.Conclusions
In summary, we identified a meta-signature, consisting
of eight highly significant and consistently dysregulated
miRNAs (miR-141, miR-21, miR-200c, miR-145, miR-
125b, miR-199a, let-7c and miR-99a) from 19 different
datasets. Using TCGA dataset, we constructed a prog-
nostic model of eight-miRNA signature, also our valid-
ation cohort confirmed that the panel may be a useful
biomarker for prognosis in BCa. We acknowledge that
prospective, large-scale, multicentre studies are neces-
sary to confirm our results before this miRNA signature
can be applied into clinical practice, and the tumorigenic
mechanisms of these miRNAs in BCa warrants further
investigated.Additional files
Additional file 1: Figure S2. Flow chart of datasets identified, included,
and excluded.
Additional file 2: Figure S1. Overview of the design strategy.
Additional file 3: Table S1. Characteristics of analyzed datasets.
Additional file 4: Table S2. Up-regulated miRNAs (n=54) reported in at
least three expression profiling studies.
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and their involvement in cancer pathogenesis in other malignancies.
Additional file 7: Figure S12. ROC curves for the 8-miRNA signature in
TCGA cohort. The ROC curve had an AUC of 0.74 (p < 0.01).
Additional file 8: Figure S3. Prognostic index and K-M analysis for
miR-141 expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and
prognostic index).
Additional file 9: Figure S4. Prognostic index and K-M analysis for
miR-200c expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and
prognostic index) (A). Each patient’ prognostic index (risk score) divided
them into high risk and low risk two groups (B). Survival analysis showed
significant difference between BCa overall survival and miRNA expression (C).
Additional file 10: Figure S5. Prognostic index and K-M analysis for
miR-21 expression in patients with bladder cancer overall survival in TCGA
datasets. Information related to censoring event being analyzed (risk
group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant
difference between BCa overall survival and miRNA expression (C).
Additional file 11: Figure S6. Prognostic index and K-M analysis for
miR-145 expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant difference
between BCa overall survival and miRNA expression (C).
Additional file 12: Figure S7. Prognostic index and K-M analysis for
miR-125b expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant difference
between BCa overall survival and miRNA expression (C).
Additional file 13: Figure S8. Prognostic index and K-M analysis for
miR-199a expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant difference
between BCa overall survival and miRNA expression (C).
Additional file 14: Figure S9. Prognostic index and K-M analysis for
let-7c expression in patients with bladder cancer overall survival in TCGA
datasets. Information related to censoring event being analyzed (risk
group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant difference
between BCa overall survival and miRNA expression (C).
Additional file 15: Figure S10. Prognostic index and K-M analysis for
miR-99a expression in patients with bladder cancer overall survival in
TCGA datasets. Information related to censoring event being analyzed
(risk group assignment, censoring status, time related to event, and prognostic
index) (A). Each patient’ prognostic index (risk score) divided them into high
risk and low risk two groups (B). Survival analysis showed significant difference
between BCa overall survival and miRNA expression (C).
Additional file 16: Figure S11. Hazard ratio of relative miRNAs and
bladder cancer overall survival in TCGA datasets.
Additional file 17: Table S5. Estimation of the hazard ratio on relative
miRNAs expression and bladder cancer overall survival in TCGA datasets.
Additional file 18: Table S6. Patients’ clinicopathological characters in
our validation cohort (N = 48).Additional file 19: Figure S13. Expression of the eight-miRNAs signature
in our validation cohort of 48 bladder cancer patients. Relative miRNA fold
change (log transformed) in bladder cancer compared with normal
adjacent tissue determined by qRT-PCR (miR-21 (A), miR-200c (B), miR-141
(C), miR-145 (D), miR-125b (E), miR-199a (F), miR-99a(G), let-7c (H)).
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